DrugBiological
Eryaspase clinical trials
Also written ERY001.
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
ERYtech Pharma (9) · Georgetown University (1) · Birgitte Klug Albertsen (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses eryaspase is read from its arms, and is right about nine times in ten.
Testing it · 11
- Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal AdenocarcinomaCompletedPhase 1Georgetown UniversityNCT04292743Written as Eryaspase
- Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginaseCompletedPhase 2Birgitte Klug AlbertsenNCT03267030Written as GRASPA
- Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PACCompletedPhase 3ERYtech PharmaNCT03665441Written as eryaspase
- Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)TerminatedPhase 2/3ERYtech PharmaNCT03674242Written as eryaspase (L-asparaginase encapsulated in red blood cells)
- GRASPA Treatment for Patients With Acute Myeloblastic LeukemiaCompletedPhase 2ERYtech PharmaNCT01810705Written as GRASPA
- GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic LeukemiaCompletedPhase 2/3ERYtech PharmaNCT01518517Written as GRASPA
- Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic LeukemiaCompletedPhase 2ERYtech PharmaNCT01523782Written as GRASPA
- Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic CancerCompletedPhase 1ERYtech PharmaNCT01523808Written as GRASPA
- Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic CarcinomaCompletedPhase 2ERYtech PharmaNCT02195180Written as ERY001
- L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBLTerminatedPhase 1ERYtech PharmaNCT01910428Written as L-asparaginase encapsulated in RBC
- Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic LeukaemiaCompletedPhase 1/2ERYtech PharmaNCT00723346Written as GRASPA
Codes
What other systems call eryaspase · ClinicalTrials.gg INT001350
- MeSH (NLM) C000708079eryaspaseOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708079 | eryaspase | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.